- Home
- AUID vs IMAB Comparison
AUID vs IMAB Comparison
Compare AUID & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- IMAB
- Stock Information
- Founded
- AUID 2009
- IMAB 2014
- Country
- AUID United States
- IMAB United States
- Employees
- AUID N/A
- IMAB N/A
- Industry
- AUID Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- IMAB Health Care
- Exchange
- AUID Nasdaq
- IMAB Nasdaq
- Market Cap
- AUID 47.3M
- IMAB 384.6M
- IPO Year
- AUID N/A
- IMAB 2020
- Fundamental
- Price
- AUID $3.11
- IMAB $3.62
- Analyst Decision
- AUID
- IMAB Strong Buy
- Analyst Count
- AUID 0
- IMAB 5
- Target Price
- AUID N/A
- IMAB $6.80
- AVG Volume (30 Days)
- AUID 50.3K
- IMAB 1.8M
- Earning Date
- AUID 11-06-2025
- IMAB 11-02-2025
- Dividend Yield
- AUID N/A
- IMAB N/A
- EPS Growth
- AUID N/A
- IMAB N/A
- EPS
- AUID N/A
- IMAB N/A
- Revenue
- AUID $2,189,524.00
- IMAB N/A
- Revenue This Year
- AUID N/A
- IMAB N/A
- Revenue Next Year
- AUID N/A
- IMAB N/A
- P/E Ratio
- AUID N/A
- IMAB N/A
- Revenue Growth
- AUID 295.86
- IMAB N/A
- 52 Week Low
- AUID $2.74
- IMAB $0.60
- 52 Week High
- AUID $9.58
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- AUID 36.32
- IMAB 44.27
- Support Level
- AUID $3.65
- IMAB $3.20
- Resistance Level
- AUID $3.93
- IMAB $4.64
- Average True Range (ATR)
- AUID 0.38
- IMAB 0.43
- MACD
- AUID -0.13
- IMAB -0.17
- Stochastic Oscillator
- AUID 20.00
- IMAB 20.49
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).